Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials
Robert E. Shapiro(University of Vermont), Amaal J. Starling(Mayo Clinic in Arizona), Erin Doty(Eli Lilly (United States)), Rashna Khanna(Eli Lilly (United States)), Ellen B. Dennehy(Purdue University West Lafayette), Paul H. Berg(Eli Lilly (United States)), Helen Hochstetler(Eli Lilly (United States))
Cited by 88
Related Papers
The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation
|Psychological Medicine|2004|989
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
|New England Journal of Medicine|2007|925
The Texas Implementation of Medication Algorithms
|The Journal of Clinical Psychiatry|2005|330